Revenue
2020
2021
2022
2023
2024
2025
Petros Pharmaceuticals, Inc. (PTPI)
Price$0.0080Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2024
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $5.1M | $5.8M | $6.0M | $7.8M | $9.6M |
| Gross profit | $0 | $3.9M | $4.2M | $3.7M | $6.2M | $5.5M |
| Gross margin | — | 76.28% | 71.98% | 61.79% | 79.52% | 57.67% |
| Research & development | — | $2.6M | $2.4M | $1.7M | $1.8M | $459,636 |
| Operating expenses | $4.6M | $4.6M | $17.8M | $23.6M | $24.3M | $22.8M |
| Operating income | −$4.6M | −$4.6M | −$13.6M | −$19.9M | −$18.0M | −$17.3M |
| Operating margin | — | −90.51% | −233.88% | −332.37% | −231.05% | −180.78% |
| EBITDA | −$4.6M | −$1.8M | −$10.3M | −$14.3M | −$11.2M | −$10.6M |
| EBITDA margin | — | −35.13% | −177.49% | −238.93% | −143.00% | −111.11% |
| Net income | $1.9M | −$14.3M | −$8.2M | −$20.0M | −$9.0M | −$20.6M |
| Net profit margin | — | −280.10% | −140.20% | −334.40% | −115.05% | −215.35% |
| Basic EPSper basic share | -$1.56 | -$83.47 | -$158.75 | -$242.00 | -$206.25 | -$962.50 |
| Diluted EPSper diluted share | -$1.56 | -$83.47 | -$158.75 | -$242.00 | -$206.25 | -$962.50 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Silverman Joshua | 8.79M |
Bernstein Bruce | 3.76M |
Boctor Fady | 894.99K |
WALKER WAYNE REMELL | 881.33K |
WEINSTEIN ROBERT | 636K |
Arnold Mitchell | 150K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data